Potential of muvalaplin as a lipoprotein(a) inhibitor.

Autor: Hooper AJ; Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.; School of Medicine, University of Western Australia, Perth, Western Australia, Australia., Fernando PMS; Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia., Burnett JR; Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.; School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Jazyk: angličtina
Zdroj: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Jan; Vol. 33 (1), pp. 5-7. Date of Electronic Publication: 2024 Feb 12.
DOI: 10.1080/13543784.2024.2302592
Databáze: MEDLINE